Earnings Releases·Nov 10, 2026, 4:22 PM ET

Palisade Bio — Third Quarter 2026 Earnings Summary

Net loss widened to $14.6 million ($0.07/share) for Q3 2026 from $2.9 million ($0.38/share) in the prior year, driven by a surge in R&D and G&A expenses to $10.6 million and $5.1 million respectively, compared to $1.4 million and $1.5 million in Q3 2025.
Cash reserves declined to $113.6 million as of September 30, 2026, from $133.4 million at year-end 2025, though management asserts current liquidity is sufficient to fund operations through key Phase 2 efficacy readouts in late 2027 and early 2028.
Clinical progress includes FDA clearance for the Crohn's disease IND in September 2026, Health Canada and Republic of Georgia regulatory clearances for the ulcerative colitis trial, and the dosing of the first patient in the global Phase 2b ASCENTRA-UC study in late October 2026.
Future milestones are projected for Q4 2027 for ASCENTRA-UC topline results and Q1 2028 for ASCENTRA-CD primary efficacy readouts, with enrollment initiation for the CD Phase 2a trial targeted for Q1 2027.
Financing activities generated $3.5 million in proceeds over the nine-month period, increasing total shares outstanding to 174.4 million, while the company reported $500,000 in license revenue for the nine months ended September 30, 2026.